Last $1.20 USD
Change Today -0.04 / -3.23%
Volume 69.8K
CASI On Other Exchanges
As of 8:10 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

casi pharmaceuticals inc (CASI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/14 - $2.34
52 Week Low
12/17/14 - $1.18
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

casi pharmaceuticals inc (CASI) Related Businessweek News

No Related Businessweek News Found

casi pharmaceuticals inc (CASI) Details

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company’s lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

15 Employees
Last Reported Date: 03/21/14
Founded in 1991

casi pharmaceuticals inc (CASI) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $285.2K
Principal Accounting Officer and Vice-Preside...
Total Annual Compensation: $175.1K
Chief Operating Officer, General Counsel and ...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

casi pharmaceuticals inc (CASI) Key Developments

CASI Pharmaceuticals, Inc. Elects Ken K. Ren as a Director

On December 3, 2014, the Board of Directors of CASI Pharmaceuticals, Inc. elected Ken K. Ren as a director of the Company, effective immediately. Dr. Ren joined CASI Pharmaceuticals in April 2012 as interim Chief Executive Officer, and after successful completion of the one-year interim period, was appointed Chief Executive Officer in April 2013. Prior to joining CASI Pharmaceuticals from 2005-2012, Dr. Ren was the president of Accelovance (China).

CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

CASI Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2014. CASI reported a net loss for the third quarter of 2014 of $21.5 million, or $0.77 per share, which includes non-cash expense of $19.7 million associated with the September 2014 in-license agreements with Spectrum Pharmaceuticals. Excluding this non-cash expense, the net loss for the third quarter was $1.9 million, or $0.07 per share, compared with a net loss of $1.4 million, or $0.05 per share, for the same period last year. CASI reported a net loss for the first nine months of 2014 of $24.6 million, or $0.90 per share, which includes the above non-cash expense associated with the in-license agreements with Spectrum Pharmaceuticals. Excluding this non-cash expense, the net loss for the first nine months of 2014 was $4.9 million, or $0.18 per share, compared with a net loss of $4.4 million, or $0.17 per share, for the first nine months of 2013. The increase in reported net loss for the quarter and nine months is primarily due to the Company's acquisition of greater China rights for three late-stage products from Spectrum Pharmaceuticals, which were acquired primarily with equity and no cash up front, and resulted in the transformation of the Company's product pipeline.

CASI Pharmaceuticals, Inc. Receives Approval from CFDA for Phase 2 Clinical Trial in China with ENMD-2076 for Soft Tissue Sarcoma

CASI Pharmaceuticals, Inc. announced that the China Food and Drug Administration (CFDA) has approved the company's application to conduct a Phase 2 clinical trial in soft tissue sarcoma patients in China with its proprietary drug candidate ENMD-2076. This is the company's second approval to begin a Phase 2 clinical trial in an oncology indication with ENMD-2076 in the country, followed by CFDA's approval in July to begin a Phase 2 trial in triple-negative breast cancer patients. ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase I clinical trials in solid tumor cancers including ovarian, breast, liver, renal and sarcoma, as well as in leukemia and multiple myeloma.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CASI:US $1.20 USD -0.04

CASI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $208.03 USD +2.28
Novartis AG SFr.91.15 CHF +2.20
Regeneron Pharmaceuticals Inc $410.99 USD +14.86
View Industry Companies

Industry Analysis


Industry Average

Valuation CASI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 48.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CASI PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at